On April 21, 2022 ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first quarter 2022 operating results (Press release, ImmunoGen, APR 21, 2022, View Source [SID1234612745]). Management will also provide a brief update on the business.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CONFERENCE CALL INFORMATION

To access the live call by phone, dial (877) 621-5803; the conference ID is 5444669. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

On April 21, 2022 Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, reported that it will report first quarter 2022 financial results on Thursday, May 5, 2022, after the U.S. financial markets close (Press release, Dynavax Technologies, APR 21, 2022, https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2022-financial-results-and-host-conference-call-on-may-5-2022-301526392.html [SID1234612881]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dynavax will host a conference call and live audio webcast on Thursday, May 5, 2022 at 4:30 p.m. (ET)/1:30 p.m. (PT).

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company’s website at View Source Alternatively, participants may dial (866) 420-4066 or (409) 217-8237 and refer to conference ID 4282730. A replay of the webcast will be available for 30 days following the live event.

On April 21, 2022 LUMICKS, a leading life science tools company that develops instruments for dynamic single-molecule and cell avidity analysis, reported that it has completed a new installation of its revolutionary z-Movi Cell Avidity Analyzer in the lab of Prof. Dirk Busch, Professor of Medical Microbiology, Immunology and Hygiene at the School of Medicine, Technical University of Munich (TUM) (Press release, LUMICKS, APR 21, 2022, View Source;utm_medium=rss&utm_campaign=new-customer-installation-of-lumicks-zmovi-cell-avidity-analyzer [SID1234612708]). The installation demonstrates the expanding interest in measuring cell avidity as a key biomarker in understanding immune oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The z-Movi instrument measures the avidity between immune cells and their targets, enabling researchers to identify the most potent immunotherapeutic effector cells. This new technology provides predictive, reproducible, and fast results at a single-cell resolution. LUMICKS’ cell avidity solutions use acoustics to measure forces and interactions between cells, with the goal of shortening the drug development cycle for adoptive cell therapies and other immunotherapies and reducing failure rates in clinical trials. First introduced in 2020, the z-Movi has found wide appeal in academic and industrial laboratories around the world, with a rapid uptake in sales in 2021.

Prof. Busch and, Dr. Elvira D’Ippolito, a senior post-doctoral researcher at the Busch Lab, noted that "A broad applicability of immunotherapy with T-cell receptor (TCR)-engineered T cells requires the fast identification of highly functional TCRs for diverse antigens. By measuring cellular avidity, we expect to select candidate TCRs for clinical application with unprecedented speed and precision."

Added Gerrit Sitters, General Manager of LUMICKS Cell Avidity Business, "This new installation demonstrates the increased recognition by leading researchers of the valuable insights to be gained by using our LUMICKS technology. We are very pleased to contribute to a better scientific understanding of how measuring cell avidity can uncover critical biomarkers that help advance immune oncology efforts worldwide. We look forward to the insights and discoveries about immune system interactions that these two labs will produce in the future."

On April 22, 2022 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") reported that it will book an impairment loss in the fourth quarter of the fiscal year ended March 31, 2022 (April 1, 2021 to March 31, 2022) and the first quarter of the fiscal year ending March 31, 2023 (April 1, 2022 to March 31, 2023) as follows (Press release, Astellas, APR 21, 2022, View Source [SID1234612747]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(1) Details of impairment loss (the fourth quarter of fiscal year 2021)
For the following reasons, Astellas will book an impairment loss of approximately ¥50 billion as other expenses in the fourth quarter of fiscal year 2021 not included in the financial forecasts (Full basis) announced on October 29, 2021.

Astellas received reports of serious adverse events in patients who participated in the ASPIRO clinical trial evaluating investigational gene therapy AT132 in patients with X-linked myotubular myopathy. In September 2021, Astellas voluntarily suspended screening and dosing. After that, Astellas received the clinical hold for the ASPIRO clinical trial from the US Food and Drug Administration (FDA). Astellas then reassessed the development plan and recognized a delay in approval timing. Astellas also revised the eligible treatment population based upon an anticipated future product label compared to our initial assessment. As a result of reevaluation of the intangible asset based on the updated assumptions, Astellas will book an impairment loss of intangible assets as other expenses.

It has decided to terminate the development of the DNA vaccine ASP2390, which is currently in Phase 1 study for house dust mite-induced allergic rhinitis patients. As a result of this termination, Astellas will book an impairment loss of intangible assets as other expenses.

It has decided to terminate the development of the GITR agonistic antibody ASP1951, which is currently in Phase 1 study for cancer patients. As a result of this termination, Astellas will book an impairment loss of goodwill as other expenses.

(2) Details of impairment loss (the first quarter of fiscal year 2022)
Based upon recent preclinical study data, the research and development of gene therapy programs AT702, AT751 and AT753 for Duchenne muscular dystrophy has been terminated. As a result of this termination, Astellas will book an impairment loss of intangible assets of $ 170 million as other expenses in the first quarter of fiscal year 2022.
Regarding (1) above, the impact from this matter is not reflected in Astellas’ consolidated financial forecasts for the fiscal year ending March 31, 2022 that were announced in October 2021. In addition to (2) above, the financial impact of this matter will be included in the announcement of financial results on April 27, 2022.

Click below for a copy of the full press release

Notice Regarding Impairment Loss for Products under Development

On April 21, 2022 Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, reported that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will participate in a fireside chat at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022 at 2:30pm ET (Press release, Inhibikase Therapeutics, APR 21, 2022, View Source;ophthalmology-conference-301530237.html [SID1234612882])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company’s website, www.inhibikase.com. An archived replay of the webcast will be available for approximately 30 days. In addition, the Company recently hosted a virtual Key Opinion Leader investor event on April 20, 2022. A replay of the event can be accessed here.